What is Kamada Pharmaceuticals?
Kamada Ltd., headquartered in Rehovot, Israel, is a biopharmaceutical company specializing in the development and commercialization of plasma-derived protein therapeutics. Founded in 1990, Kamada focuses on orphan indications, addressing unmet medical needs in rare diseases. The company boasts a robust product portfolio and a promising late-stage pipeline, positioning it as a key player in the specialized therapeutics market. Its strategic focus on plasma-derived therapies highlights a commitment to innovative treatments for complex conditions.
How much funding has Kamada Pharmaceuticals raised?
Kamada Pharmaceuticals has raised a total of $36.4M across 2 funding rounds:
Share Placement
$25M
Other Financing Round
$11.4M
Share Placement (2020): $25M with participation from FIMI Opportunity Funds
Other Financing Round (2022): $11.4M, investors not publicly disclosed
Key Investors in Kamada Pharmaceuticals
FIMI Opportunity Funds
FIMI Opportunity Funds is a prominent investment firm known for providing capital to companies across various sectors, likely focusing on strategic growth and expansion opportunities.
What's next for Kamada Pharmaceuticals?
The recent major strategic investment signals a pivotal phase for Kamada Pharmaceuticals, likely enabling the acceleration of its late-stage product pipeline and the expansion of its commercial operations. This infusion of capital is expected to support further research and development, potentially leading to new therapeutic approvals and market entries. The company's focus on orphan indications suggests a strategy geared towards high-impact, specialized treatments, with this latest backing poised to enhance its competitive standing and capacity for innovation in the biopharmaceutical landscape.
See full Kamada Pharmaceuticals company page
